Medical articles today

/* 728x15, */

Medtronic Demonstrates Concrete Results On First Pacemaker Designed For Use With MRI

Distinct data announced at Heart Rhythm 2009, the annual congress of the Passion Rhythm Society, show that patients implanted with the investigational EnRhythm MRI™ SureScan™ pacing operation experienced no complications related to the application of attractive resonance imaging (MRI). Sponsored by Medtronic, Inc. (NYSE: MDT), the study confirms that the pacing manner can help cardiac device patients benefit from the apply of MRI, a critical imaging mode commonly used in disease diagnosis. Currently, due to safety considerations, there are no implantable pacemakers or defibrillators approved for use with MRI in the United States.

UPMC Cardiovascular College Recruiting For Severe Coronary Love Disease Study

The UPMC Cardiovascular Institute currently is enrolling participants for a Phase 2 clinical proof to scrutinize if administering a naturally occurring protein improves blood work to the cardiac muscle in patients with severe coronary artery disease. The study, familiar as Angiogenesis for the Treatment of Coronary Heart Disease (ACORD), is a randomized, double-blind, placebo-controlled trial that compares the employ of a protein at three dose levels with a placebo. The therapy is delivered to the heart muscle by threading a catheter washed-up a meager intersect in the upper leg. "Other studies hog hinted that this approach can incision the severity of quinsy in patients who have very tired all other treatment options, " said Oscar Marroquin, M.

/* 468x60, */

Heart Charity Calls For The Government To Dab Harder On Palliative Affliction

In response to the Territory of Commons Typical Accounts Commitee End of Life Carefulness Announcement published Ruairi O'Connor, Tendency of Policy and Common Affairs at the British Feelings Foundation (BHF) said: "Today's report strongly supports points made by the 40 members of the Cardio and Vascular Coalition in its recent Destination 2020 document. Inured the State Assistance Framework for Coronary Heart Disease is instanter ten years old, the CVC is calling for a renewed strategic approach to cardio and vascular disease, from prevention through to end of activity care. "Many cardiac and vascular patients are affected by issues highlighted in the report and assume less specialist palliative care compared to other conditions.

Formulations Of Three Aspirin Types Compared By Study

For many years, it has been known that aspirin is salutary to patients suffering affection attacks and near-heart attacks. Nevertheless which of the legion contradistinct types of aspirin is likely to help the most? A group of researchers led by Dr. Sean Nordt from the University of California, San Diego gave three disparate types of aspirin to a group of volunteer test subjects: popular aspirin swallowed whole, regular aspirin chewed and swallowed, and chewable aspirin chewed and swallowed. Blood levels of aspirin were then measured, to look which route led to the highest aspirin levels in the body. The chewable aspirin consistently showed more advantageous and extra close absorption than the universal aspirin, if swallowed integral or chewed.

Policies On Organ Donation After Cardiac Destruction Vary Substantially Among Children's Hospitals

Although a blimp cipher of children's hospitals have developed or are developing policies regarding organ donation after cardiac death, there is appreciable variation among policies, including the criteria for declaring death, according to a glance at in the May 13 argument of JAMA. Donation after cardiac death (DCD) potentially permits patients who do not conformed the neurological criteria for curtains to donate solid organs. "Controlled DCD occurs consequent planned withdrawal of life-sustaining treatment, and uncontrolled DCD occurs after unanticipated cardiac arrest. Credible controlled DCD donors consist of patients with irreversible catastrophic brain injury or end-stage neuromuscular diseases, " the authors write.

/* 468x60, */

Medtronic Completes Enrollment In International Post-Market Study Of Resolute Drug-Eluting Stent

Medtronic, Inc. (NYSE: MDT), announced completion of enrollment in RESOLUTE International, a post-market study of its Resolute Drug-Eluting Stent (DES). One-year data from this international study, which enrolled 2, 464 patients at 88 sites from 17 countries in Europe, Asia, Africa, and Latin America, are expected in the second half of 2010. "RESOLUTE International will expand our empiricism and understanding of the Resolute DES in the setting of sample clinical practice, which affords a measure of diversity in patient types and lesion characteristics that are typically not bright-eyed represented in tightly controlled clinical trials, " said Prof.

Rocket: [100]
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy